Pfizer is once again confronting a major patent cliff, similar to the one it faced in the early 2010s when it lost exclusivity on several high-revenue drugs including Lipitor, Protonix, and Geodon. During that period, Lipitor’s annual sales declined significantly from a peak of $12.9 billion following the entry of generic competitors.
A new round of expirations is set to affect some of Pfizer’s current top-selling products. By 2028, the company will lose exclusivity on Eliquis, Ibrance, Xtandi, and Prevnar 13. Industry estimates indicate that more than $236 billion in global branded drug sales will be exposed to generic and biosimilar competition by 2030.
Blockbuster drugs facing the patent cliff
The coming wave of expirations, often referred to as the “patent cliff,” is expected to reshape the pharmaceutical landscape. For Pfizer, the financial stakes are high, with billions in annual revenue tied to products approaching the end of their market exclusivity.
Among the company’s most affected drugs are:
- Eliquis – Anticoagulant; $7.4 billion in 2024 sales; patent expires in 2027
- Ibrance – Breast cancer treatment; patent expires in 2027
- Xtandi – Prostate cancer therapy; patent expires in 2027
- Prevnar 13 – Pneumococcal vaccine; patent expires in 2026
Strategic response through cost cuts, launches, and M&A
Pfizer is pursuing a multi-pronged strategy to address the anticipated revenue decline tied to a wave of patent expirations between 2026 and 2028. The company expects to lose about $17 to $18 billion in annual revenue during this period. In response, it has focused on operational savings, announcing $3.5 billion in cost reductions in 2024 and an additional $1.7 billion in targeted reductions through 2027.
New product launches, particularly in oncology, form another key pillar of Pfizer’s growth strategy. Padcev, an antibody-drug conjugate developed with Astellas, is a central focus. The company also expanded its cancer pipeline through a licensing deal with Nona Biosciences. These efforts follow the $43 billion acquisition of Seagen in 2023, which significantly strengthened Pfizer’s position in immunotherapy and antibody-drug conjugates.
Patents related to Eliquis, Ibrance, Xtandi, and Prevnar
Pfizer’s recent patent filings reflect its dedication to advancing next-generation healthcare solutions, with innovations spanning pediatric drug delivery, solid-state cancer formulations, resistance-overcoming cancer combinations, and streamlined vaccine compositions.
A novel oral anticoagulant for the treatment of thromboembolic disorders
Blood clots can lead to serious health problems like deep vein thrombosis (clots in the legs), pulmonary embolism (clots in the lungs), and stroke (clots in the brain). Traditional blood thinners, such as warfarin, have been used for years to prevent clots, but they often require frequent blood tests and come with strict food and drug restrictions.
U.S. Patent No. 6,967,208 introduces a new class of lactam-containing compounds that act as Factor Xa inhibitors, blocking a key enzyme involved in blood clot formation to help reduce the risk of dangerous clots. The patent also covers various forms of these compounds, including salts and prodrugs (inactive versions that activate in the body), and describes how they can be formulated into safe and effective medications for preventing or treating clot-related conditions.
The patent, titled “Lactam-containing compounds and derivatives thereof as factor Xa inhibitors,” was filed on September 17, 2002, by Bristol-Myers Squibb Pharma Co. and was granted on November 22, 2005. It is scheduled to expire on April 9, 2027, after term adjustments. The listed inventors are Donald J. P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y. S. Lam, and Stephanie L. Koch. Legal representation was provided by Venable LLP, with attorneys John Murnane, Nicholas Kallas, Lawrence Perry et al. listed on the application.
In 2007, Bristol-Myers Squibb entered into a global collaboration with Pfizer to develop and commercialize apixaban, the compound developed under this patent. The partnership combines Bristol-Myers Squibb’s cardiovascular expertise with Pfizer’s global commercial capabilities, expanding access to this novel anticoagulant therapy under the brand name Eliquis®.
Cell growth inhibitor for treating cancer, inflammation, and autoimmune diseases
Uncontrolled cell growth is a key factor in many serious health problems, including cancer, and long-term inflammation like rheumatoid arthritis and psoriasis. These problems are often linked to certain enzymes in the body, called cyclin-dependent kinases (CDKs), that help control how and when cells divide. When these enzymes become too active, they can cause cells to grow in harmful ways.
U.S. Patent RE47,739 introduces a group of specially designed compounds that block one of these key enzymes, Cdk4, and sometimes Cdk6. These compounds work by targeting the root cause of abnormal cell growth and are continuously being developed to help treat a range of diseases, including cancer, autoimmune disorders, chronic inflammation, and even certain viral infections that rely on the body’s cell cycle to spread. This patent serves as the foundation for palbociclib, the active ingredient in Ibrance®.
The patent also includes different versions of the compounds, such as salt forms, inactive forms that become active in the body (prodrugs), and slightly different chemical structures (stereoisomers and isotopically labeled versions). These variations can widen how the compounds are used and improve their potential benefits.
The patent, titled “2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones”, was filed on July 27, 2018, by Warner-Lambert Company LLC and was granted on November 26, 2019. It is set to expire on March 5, 2027. The listed inventors include Mark Barvian, Richard John Booth, John Quinn III, Joseph Thomas Repine, Derek J. Sheehan, Peter Lawrence Toogood, Scott Norman Vanderwel, and Hairong Zhou. Legal representation was provided by Dechert LLP, with attorneys Kevin Flannery, Michael Fisher, Jonathan Loeb et al. named on the application. Warner-Lambert became part of Pfizer following a 2000 acquisition, which combined two of the industry’s fastest-growing companies.
Androgen receptor inhibitor for advanced prostate cancer
Prostate cancer is the most common cancer in men, particularly in Western countries. While early cases are often curable, many progress to advanced stages treated with hormone therapy. Over time, resistance can develop, leading to hormone refractory prostate cancer (HRPC).
U.S. Patent No. 7,709,517 covers a new type of compound designed to block androgen receptors more effectively than older drugs like bicalutamide (Casodex®). These compounds are built to remain strong blockers even when the cancer becomes resistant, helping to stop tumor growth and slow the spread of advanced prostate cancer.
The patent, titled “Diarylhydantoin compounds”, was filed on May 15, 2006, by the University of California, San Diego, and was granted on May 4, 2010. It has an adjusted expiration date of December 28, 2027. The listed inventors include Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat, and Dongwon Yoo. Legal representation was provided by Nixon & Vanderhye, with attorneys Harold Burnam, Bryan Davidson, Jeffry Nelson et al. named on the application.
Xtandi, a prostate cancer drug developed by UCLA researchers and the Howard Hughes Medical Institute, was licensed to Medivation in 2005 and later acquired by Pfizer for $14 billion in 2016. Now co-marketed with Astellas, Xtandi has become a blockbuster therapy.
Expanded pneumococcal vaccine for broader protection
Pneumococcal disease, caused by Streptococcus pneumoniae, is a serious health concern for infants and young children, often leading to conditions such as meningitis, pneumonia, and bloodstream infections.
U.S. Patent No. 7,955,605 builds on earlier vaccines by introducing a 13-valent pneumococcal conjugate vaccine (13vPnC) designed to offer broader protection. The vaccine targets 13 different types of the bacteria, including the original seven covered by earlier vaccines, 4, 6B, 9V, 14, 18C, 19F, and 23F, plus six additional types: 1, 3, 5, 6A, 7F, and 19A. Each bacterial sugar is chemically linked to a carrier protein (CRM197) to help the immune system recognize and respond effectively. An aluminum phosphate adjuvant is also included to boost the vaccine’s effectiveness, particularly in infants and toddlers.
The patent, titled “Multivalent pneumococcal polysaccharide-protein conjugate composition”, was filed on December 22, 2006, by Wyeth LLC and granted on June 7, 2011. It has an expiration date of March 31, 2026. The listed inventor is A. Krishna Prasad. Legal representation was provided by Pfizer Inc., with attorneys Bryan Zielinski, Jeffrey Rennecker, Jeffrey Myers et al. named on the application.
Wyeth became part of Pfizer in a $68 billion acquisition announced in 2009, a move that expanded Pfizer’s vaccine portfolio and solidified its position as a leader in pediatric immunization.
Pfizer: Patenting activity
Pfizer’s global patent filing activity reached its peak in 2020, coinciding with the rapid development of its COVID-19 vaccine and the urgent need to secure intellectual property around related technologies. The 2015 surge coincided with the $17 billion acquisition of Hospira, which significantly expanded Pfizer’s Global Established Pharmaceutical business with a portfolio of sterile injectable drugs and biosimilars.
The years between these peaks saw steady activity as Pfizer advanced its oncology and vaccine pipelines, including its 2018 collaboration with BioNTech on mRNA-based flu vaccines, which laid the groundwork for its pandemic response.
In focus: Blockbuster drugs patent trends
Pfizer’s patent filings on its blockbuster drugs reached a peak in 2020 as the company worked to reinforce exclusivity ahead of approaching expirations. Eliquis showed superior outcomes in cancer-related venous thromboembolism, enhancing its clinical and market profile.
Pfizer also reformulated Ibrance from capsules to tablets, a strategy commonly used to extend market exclusivity. Meanwhile, promising Phase 3 trial results for Xtandi further supported its long-term market potential, contributing to the surge in patent activity.
Pfizer’s blockbuster drugs accounted for a significant portion of its total patent filings. Prevnar accounted for the largest portion among them, followed by Ibrance, Eliquis, and Xtandi. These made up just 15.5 percent of the company’s total filings, with Prevnar at 8.1 percent, Ibrance at 3.2 percent, Eliquis at 2.2 percent, and Xtandi at 2 percent. The remaining 84.5 percent were linked to other assets across Pfizer’s broader portfolio.
Between 2026 and 2027, Pfizer faces relatively few blockbuster drug patent expirations, with only 32 patents expiring in 2026 and nine the following year. This limited exposure is largely due to the fact that foundational patents for some of Pfizer’s top-selling drugs, including Eliquis, Ibrance, Xtandi, and Prevnar, were not originally assigned to Pfizer. These core patents were developed by other companies or research institutions, such as Bristol-Myers Squibb, Warner-Lambert, the University of California, and Wyeth, which Pfizer later partnered with or acquired.
However, subsequent patents related to these products, including innovations in formulation, delivery, and combination therapies, are now held under Pfizer’s name. As a result, the relatively low number of expirations in the near term gives way to a sharp increase beginning in 2036, when patents tied to Pfizer’s in-house developments begin to lapse.
Pfizer: Top Technology Areas
Pfizer’s global patent activity emphasizes traditional pharmaceutical R&D, with nearly 60% of filings centered on medical preparations (A61K) and specific therapeutic activity of compounds (A61P). Significant filings in peptides (C07K) and heterocyclic compounds (C07D) indicate a strong focus on molecular-level drug design and biologics. Additional activity in microbiological or enzymatic processes (C12N) supports its interest in biotech-driven therapies.
Smaller clusters in general organic chemistry (C07B), climate adaptation technologies (Y02A), and non-standard compound classes (C07F) suggest exploratory efforts in chemistry and sustainability.
Pfizer: Top Legal Representatives
Pfizer relied on a core group of legal experts for its global patent filings, including top law firms like Smart & Biggar and its in-house team led by Bryan C. Zielinski, Pfizer’s Chief Patent Counsel. Other notable representatives include Miyuki Tatsuta, , also part of Pfizer’s in-house team, along with Yomoto Yoshihisa, and the European Patent Department, reflecting Pfizer’s coordinated use of international and in-house legal expertise to support its global patent portfolio.
